Pfizer shares have been downgraded to neutral from overweight by JP Morgan Chase. "We clearly have seen a positive shift in Pfizer's narrative, which is now focused on the re-acceleration of the company's top and bottom line growth beyond 2020," J.P. Morgan's Chris Schott said about the pharmaceutical company.
"However, with the company now trading in line with peers and the broader market, we see this improved core story as better reflected in valuation," Schott stressed. "And with further upside to shares likely tied to either additional pipeline success or positive new launch momentum (largely 2020+ events), we are moving to the sidelines."
Lyrica, which generated around $5 billion in sales for Pfizer last year, was granted a six-month patent exclusivity extension by the U.S. Food & Drug Administration last month, but the branded treatment, known also as pregabalin, will face generic competition from June of next year.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PFE declined for three days, in of 318 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for PFE moved out of overbought territory on May 07, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for PFE crossed bearishly below the 50-day moving average on April 08, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on May 01, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on May 03, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on May 01, 2024. You may want to consider a long position or call options on PFE as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on May 01, 2024. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on May 01, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.763) is normal, around the industry mean (5.632). P/E Ratio (74.919) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.281) is also within normal values, averaging (3.004). Dividend Yield (0.060) settles around the average of (0.164) among similar stocks. P/S Ratio (2.674) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor